LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.1 Million TWD | 104.22% |
| 2022 | -120.9 Million TWD | -365.36% |
| 2021 | 45.56 Million TWD | 434.7% |
| 2020 | -13.61 Million TWD | -589.32% |
| 2019 | 2.78 Million TWD | 212.23% |
| 2018 | 891 Thousand TWD | -98.91% |
| 2017 | 81.91 Million TWD | 30.44% |
| 2016 | 62.79 Million TWD | 160.7% |
| 2015 | -103.45 Million TWD | -775.99% |
| 2014 | 15.3 Million TWD | -94.72% |
| 2013 | 289.77 Million TWD | 598.31% |
| 2012 | -58.15 Million TWD | -262.52% |
| 2011 | 35.78 Million TWD | -69.49% |
| 2010 | 117.28 Million TWD | 35.1% |
| 2009 | 86.81 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -23.15 Million TWD | -798.94% |
| 2024 Q2 | 3.31 Million TWD | 136.29% |
| 2024 Q1 | -9.12 Million TWD | -170.77% |
| 2023 Q3 | -14.62 Million TWD | -62.29% |
| 2023 Q2 | -9 Million TWD | -156.89% |
| 2023 Q1 | 15.83 Million TWD | 229.98% |
| 2023 FY | 5.1 Million TWD | 104.22% |
| 2023 Q4 | 12.89 Million TWD | 188.22% |
| 2022 Q2 | -78.47 Million TWD | -324.37% |
| 2022 FY | -120.9 Million TWD | -365.36% |
| 2022 Q4 | -12.18 Million TWD | -2.99% |
| 2022 Q1 | -18.49 Million TWD | -278.2% |
| 2022 Q3 | -11.82 Million TWD | 84.93% |
| 2021 FY | 45.56 Million TWD | 434.7% |
| 2021 Q1 | 11.43 Million TWD | 96.53% |
| 2021 Q2 | 110.14 Million TWD | 863.35% |
| 2021 Q3 | -86.39 Million TWD | -178.44% |
| 2021 Q4 | 10.37 Million TWD | 112.01% |
| 2020 Q2 | 17.77 Million TWD | 212.29% |
| 2020 Q1 | -15.82 Million TWD | -303.67% |
| 2020 FY | -13.61 Million TWD | -589.32% |
| 2020 Q4 | 5.81 Million TWD | 127.22% |
| 2020 Q3 | -21.37 Million TWD | -220.27% |
| 2019 FY | 2.78 Million TWD | 212.23% |
| 2019 Q2 | -14.5 Million TWD | -180.2% |
| 2019 Q3 | 3.12 Million TWD | 121.51% |
| 2019 Q1 | 18.09 Million TWD | 62.41% |
| 2019 Q4 | -3.92 Million TWD | -225.63% |
| 2018 Q3 | -20.15 Million TWD | -61.35% |
| 2018 Q2 | -12.49 Million TWD | -155.77% |
| 2018 Q4 | 11.13 Million TWD | 155.26% |
| 2018 FY | 891 Thousand TWD | -98.91% |
| 2018 Q1 | 22.4 Million TWD | -2.4% |
| 2017 Q4 | 22.95 Million TWD | -24.92% |
| 2017 Q1 | 44.95 Million TWD | 802.67% |
| 2017 Q2 | -16.56 Million TWD | -136.85% |
| 2017 Q3 | 30.57 Million TWD | 284.53% |
| 2017 FY | 81.91 Million TWD | 30.44% |
| 2016 Q4 | 4.98 Million TWD | -83.56% |
| 2016 Q1 | 22.14 Million TWD | 145.66% |
| 2016 FY | 62.79 Million TWD | 160.7% |
| 2016 Q2 | 5.38 Million TWD | -75.68% |
| 2016 Q3 | 30.29 Million TWD | 462.49% |
| 2015 Q1 | -16.89 Million TWD | -17.88% |
| 2015 FY | -103.45 Million TWD | -775.99% |
| 2015 Q4 | -48.49 Million TWD | -141.74% |
| 2015 Q3 | -20.05 Million TWD | -11.36% |
| 2015 Q2 | -18.01 Million TWD | -6.64% |
| 2014 Q4 | -14.32 Million TWD | -140.66% |
| 2014 FY | 15.3 Million TWD | -94.72% |
| 2014 Q1 | 29.06 Million TWD | 90.82% |
| 2014 Q2 | 6.51 Million TWD | -77.57% |
| 2014 Q3 | -5.95 Million TWD | -191.33% |
| 2013 Q4 | 15.23 Million TWD | -86.21% |
| 2013 FY | 289.77 Million TWD | 598.31% |
| 2013 Q1 | 83.01 Million TWD | 636.65% |
| 2013 Q2 | 81.06 Million TWD | -2.36% |
| 2013 Q3 | 110.46 Million TWD | 36.26% |
| 2012 Q3 | -46.8 Million TWD | -1389.83% |
| 2012 Q1 | 581 Thousand TWD | -96.57% |
| 2012 FY | -58.15 Million TWD | -262.52% |
| 2012 Q4 | -15.47 Million TWD | 66.95% |
| 2012 Q2 | 3.62 Million TWD | 524.61% |
| 2011 Q2 | -28.12 Million TWD | -230.68% |
| 2011 Q3 | 25.43 Million TWD | 190.42% |
| 2011 Q4 | 16.95 Million TWD | -33.34% |
| 2011 FY | 35.78 Million TWD | -69.49% |
| 2011 Q1 | 21.52 Million TWD | 729.88% |
| 2010 Q2 | -1.29 Million TWD | -106.9% |
| 2010 FY | 117.28 Million TWD | 35.1% |
| 2010 Q3 | 103.23 Million TWD | 8077.82% |
| 2010 Q1 | 18.76 Million TWD | 0.0% |
| 2010 Q4 | -3.41 Million TWD | -103.31% |
| 2009 FY | 86.81 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Grape King Bio Ltd | 1.45 Billion TWD | 99.649% |
| Standard Chem & Pharm CO., LTD. | 834.88 Million TWD | 99.389% |
| Maywufa Company Ltd. | 169.09 Million TWD | 96.982% |
| ScinoPharm Taiwan, Ltd. | 287.05 Million TWD | 98.222% |
| Lotus Pharmaceutical Co., Ltd. | 4.1 Billion TWD | 99.876% |
| YungShin Global Holding Corporation | 827.3 Million TWD | 99.383% |
| PhytoHealth Corporation | -47.11 Million TWD | 110.83% |
| SCI Pharmtech, Inc. | 294.72 Million TWD | 98.269% |
| Formosa Laboratories, Inc. | 126.24 Million TWD | 95.958% |
| PharmaEssentia Corporation | -623.83 Million TWD | 100.818% |
| Bora Pharmaceuticals Co., LTD. | 3.03 Billion TWD | 99.832% |